BioLineRx Gross Profit from 2010 to 2025

BLRX Stock

USD 3.58 0.16 4.68%

BioLineRx Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 947.3 K in 2025. Gross Profit is the profit BioLineRx makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2009-12-31

Previous Quarter

4.5 M

Current Value

4.1 M

Quarterly Volatility

23.7 M

Credit Downgrade

Yuan Drop

Covid

Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 2.6 M or Selling General Administrative of 20.1 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.44. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.

Check out the analysis of BioLineRx Correlation against competitors.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of BioLineRx over the last few years. Gross profit is a required income statement account that reflects total revenue of BioLineRx minus its cost of goods sold. It is profit before BioLineRx operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. BioLineRx's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 15.12 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

BioLineRx Gross Profit Regression Statistics

	Arithmetic Mean	18,254,842
	Geometric Mean	0.00
	Coefficient Of Variation	212.63
	Mean Deviation	27,409,321
	Median	0.00
	Standard Deviation	38,814,432
	Sample Variance	1506.6T
	Range	114.1M
	R-Value	(0.57)
	Mean Square Error	1093.4T
	R-Squared	0.32
	Significance	0.02
	Slope	(4,630,836)
	Total Sum of Squares	22598.4T

BioLineRx Gross Profit History

	2025	947.3 K
	2024	997.2 K
	2023	1.1 M
	2022	-654 K
	2021	-702 K
	2020	-934 K
	2019	-940 K

Other Fundumenentals of BioLineRx

Gross Profit Margin

BioLineRx Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Net Tangible Assets	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total	Capital Surpluse
Total Assets		0.53	0.6	0.78	0.76	0.49	0.75	0.69	0.65	0.71	0.57	-0.79	0.01	0.86	0.65	0.67	0.62	-0.11	-0.3	0.65	-0.19	-0.19
Total Stockholder Equity	0.53		-0.3	0.14	0.51	-0.45	0.24	-0.16	0.33	-0.03	-0.11	0.02	-0.06	0.52	-0.2	0.49	-0.2	0.68	0.46	-0.19	0.38	0.38
Accounts Payable	0.6	-0.3		0.75	0.39	0.96	0.59	0.9	0.47	0.8	0.76	-0.88	0.03	0.45	0.91	0.24	0.89	-0.67	-0.73	0.89	-0.71	-0.71
Long Term Debt	0.78	0.14	0.75		0.45	0.7	0.85	0.8	0.45	0.79	0.7	-0.86	0.15	0.52	0.82	0.3	0.79	-0.23	-0.52	0.77	-0.42	-0.42
Short Term Investments	0.76	0.51	0.39	0.45		0.28	0.29	0.49	0.52	0.55	0.55	-0.54	-0.13	0.95	0.29	0.94	0.25	0.03	0.01	0.47	-0.16	-0.16
Total Liab	0.49	-0.45	0.96	0.7	0.28		0.49	0.92	0.32	0.81	0.73	-0.83	0.04	0.36	0.89	0.17	0.87	-0.75	-0.74	0.91	-0.75	-0.75
Intangible Assets	0.75	0.24	0.59	0.85	0.29	0.49		0.54	0.61	0.47	0.52	-0.78	0.1	0.35	0.74	0.12	0.74	-0.27	-0.63	0.49	-0.1	-0.1
Common Stock	0.69	-0.16	0.9	0.8	0.49	0.92	0.54		0.32	0.96	0.66	-0.9	-0.08	0.61	0.88	0.42	0.84	-0.48	-0.51	1.0	-0.67	-0.67
Property Plant Equipment	0.65	0.33	0.47	0.45	0.52	0.32	0.61	0.32		0.22	0.56	-0.57	-0.14	0.47	0.51	0.34	0.52	-0.31	-0.52	0.27	-0.11	-0.11
Current Deferred Revenue	0.71	-0.03	0.8	0.79	0.55	0.81	0.47	0.96	0.22		0.59	-0.82	-0.05	0.69	0.78	0.52	0.73	-0.26	-0.3	0.97	-0.61	-0.61
Net Debt	0.57	-0.11	0.76	0.7	0.55	0.73	0.52	0.66	0.56	0.59		-0.71	0.24	0.45	0.65	0.34	0.62	-0.52	-0.65	0.64	-0.53	-0.53
Retained Earnings	-0.79	0.02	-0.88	-0.86	-0.54	-0.83	-0.78	-0.9	-0.57	-0.82	-0.71		0.13	-0.61	-0.92	-0.44	-0.89	0.51	0.65	-0.87	0.44	0.44
Net Receivables	0.01	-0.06	0.03	0.15	-0.13	0.04	0.1	-0.08	-0.14	-0.05	0.24	0.13		-0.15	-0.14	-0.19	-0.16	-0.04	-0.11	-0.07	0.07	0.07
Total Current Assets	0.86	0.52	0.45	0.52	0.95	0.36	0.35	0.61	0.47	0.69	0.45	-0.61	-0.15		0.4	0.93	0.36	0.03	0.02	0.6	-0.22	-0.22
Short Term Debt	0.65	-0.2	0.91	0.82	0.29	0.89	0.74	0.88	0.51	0.78	0.65	-0.92	-0.14	0.4		0.15	0.99	-0.61	-0.77	0.87	-0.59	-0.59
Net Tangible Assets	0.67	0.49	0.24	0.3	0.94	0.17	0.12	0.42	0.34	0.52	0.34	-0.44	-0.19	0.93	0.15		0.1	0.12	0.2	0.42	-0.03	-0.03
Short Long Term Debt	0.62	-0.2	0.89	0.79	0.25	0.87	0.74	0.84	0.52	0.73	0.62	-0.89	-0.16	0.36	0.99	0.1		-0.62	-0.79	0.82	-0.57	-0.57
Net Invested Capital	-0.11	0.68	-0.67	-0.23	0.03	-0.75	-0.27	-0.48	-0.31	-0.26	-0.52	0.51	-0.04	0.03	-0.61	0.12	-0.62		0.88	-0.47	0.42	0.42
Net Working Capital	-0.3	0.46	-0.73	-0.52	0.01	-0.74	-0.63	-0.51	-0.52	-0.3	-0.65	0.65	-0.11	0.02	-0.77	0.2	-0.79	0.88		-0.48	0.38	0.38
Capital Stock	0.65	-0.19	0.89	0.77	0.47	0.91	0.49	1.0	0.27	0.97	0.64	-0.87	-0.07	0.6	0.87	0.42	0.82	-0.47	-0.48		-0.69	-0.69
Long Term Debt Total	-0.19	0.38	-0.71	-0.42	-0.16	-0.75	-0.1	-0.67	-0.11	-0.61	-0.53	0.44	0.07	-0.22	-0.59	-0.03	-0.57	0.42	0.38	-0.69		1.0
Capital Surpluse	-0.19	0.38	-0.71	-0.42	-0.16	-0.75	-0.1	-0.67	-0.11	-0.61	-0.53	0.44	0.07	-0.22	-0.59	-0.03	-0.57	0.42	0.38	-0.69	1.0

Click cells to compare fundamentals

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	997.2 K	947.3 K
Gross Profit Margin	0.27	0.25

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC